Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivax to join Zocor court battle

Executive Summary

Ivax files suit against FDA on Nov. 7 claiming exclusivity rights for Merck's cholesterol-lowering agent Zocor (simvastatin) following an Oct. 24 letter from the agency denying its citizen petition. Ivax claims exclusivity rights for Zocor 5 mg, 10 mg, 20 mg and 40 mg strengths and seeks to have two Merck patents re-listed in the "Orange Book." Ranbaxy filed suit against FDA Sept. 16 claiming exclusivity rights for the 80 mg dose of Zocor (1"The Pink Sheet" Oct. 31, 2005, p. 19). Both Ivax and Ranbaxy need a quick win to settle the matter; the compound patent for Zocor is set to expire June 23, 2006...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046576

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel